Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Subscribe to Search results

Scotland introduced self-declaration regarding impact of Hepatitis C.

Published on: 22 July, 2024

The Prime Minister announced additional funding for EIBSS.

Published on: 22 July, 2024

Announcements of reforms to IBPS (NI).

Published on: 22 July, 2024

The Government announced changes to the schemes to address disparities.

Published on: 22 July, 2024

Alpha interferon was licensed for the treatment of Hepatitis C in the UK.

Published on: 22 July, 2024

Patients reported difficulties accessing alpha interferon treatment.

Published on: 22 July, 2024

UKHCDO confirmed recombinant Factor 8 as the safest product available for the treatment of people with bleeding disorders.

Published on: 22 July, 2024

Wales adopted policy of recombinant Factor 8 for all Haemophilia A patients.

Published on: 22 July, 2024

The Secretary of State for Health announced that recombinant products were to be made available for all children under 16 and previously untreated patients in England.

Published on: 22 July, 2024

Scotland and Northern Ireland confirmed that all haemophilia patients would be placed on recombinant treatment.

Published on: 22 July, 2024

Ministers in England accepted recommendation for recombinant to be made available for all adult haemophilia patients on a phased basis over a 4-5 year period starting in 2002-03.

Published on: 22 July, 2024

Hepatitis C Strategy for England was published.

Published on: 22 July, 2024

NICE recommended alpha interferon and ribavirin combination therapy for the treatment of moderate to severe Hepatitis C

Published on: 22 July, 2024

The Haemophilia Society led campaign for full access to recombinant Factor 8.

Published on: 22 July, 2024

Pegylated interferon monotherapy was licensed in the UK.

Published on: 22 July, 2024

Hepatitis C Action Plan for Scotland was published.

Published on: 22 July, 2024

Action Plan for the Prevention, Treatment and Control of Hepatitis C in Northern Ireland was published.

Published on: 22 July, 2024

Blood Borne Viral Hepatitis Action Plan for Wales was published.

Published on: 22 July, 2024

DAAs were licensed and became available for Hepatitis C treatment in the UK.

Published on: 22 July, 2024

The main treatment for Hepatitis C became sofosbuvir combined with other agents.

Published on: 22 July, 2024

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 2215
  • Page 2216
  • Page 2217
  • Page 2218
  • Current page 2219
  • Page 2220
  • Page 2221
  • Page 2222
  • Page 2223
  • …
  • Next page Next
  • Last page Last

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.